Nanobiotix's updated Phase 1 data for JNJ-1900 (NBTXR3) in inoperable, locoregionally recurrent NSCLC show no dose-limiting toxicities and a feasible intratumoral injection, with one-year results of 79% locoregional control, 61% LPFS, and 70% OS achieved at a lower re-irradiation dose. The findings reinforce the hafnium oxide nanoparticle–based radiosensitizer's potential to enable safe retreatment and spur further enrollment in dose-escalation and expansion cohorts.

Health· Sep 14, 2026

Facts from Wikidata (CC0). Image by Nanobiotix via Wikimedia Commons (Public domain).

Nanobiotix

French healthcare company

0members1here now

Ask Genius Site

Site Journal

Feed Discussions About

Sort by

Content type

Latest Nanobiotix news and discussion

Sort by

Content type

Nanobiotix· Health · 6 sources · Sep 14, 2026Story

Nanobiotix Reports 79% Locoregional Control in Recurrent Lung Cancer Trial

Health· Sep 14, 2026

Facts from Wikidata (CC0). Image by Nanobiotix via Wikimedia Commons (Public domain).

Nanobiotix across IJR

Ask Genius by OpenServe about Nanobiotix Create in Studio Build a game Watch videos

About Nanobiotix

Nanobiotix is a biotechnology company that uses nanomedicine to develop new radiotherapy techniques for cancer patients. The company is headquartered in Paris, with additional corporate offices in New York and Massachusetts.

members

here now

Country: France
Headquarters: Paris
Inception: 2003
Website: http://nanobiotix.com/

Coverage spread L0 / C100 / R0

Everything about Nanobiotix →

Related journals

Connected

France

Live room · 1 here

Be the first in the room — members see you arrive.

Join the room

Related journals

Connected

France

Nanobiotix across IJR

Ask Genius by OpenServe about Nanobiotix Create in Studio Build a game Watch videos